As part of its advocacy program in the United States, ACRO submits regulatory comments to U.S. regulators. This comment letter, submitted by ACRO to the FDA in 2025 on the ICH E21 guideline on the Inclusion of Pregnancy and Breastfeeding Individuals in Clinical Trials, can be found below.